United States securities and exchange commission logo





                          August 29, 2023

       Daniel J. O'Connor
       President and Chief Executive Officer
       New Ambrx Biopharma Inc.
       10975 North Torrey Pines Road
       La Jolla, California 92037

                                                        Re: New Ambrx Biopharma
Inc.
                                                            Registration
Statement on Form S-4
                                                            Filed August 25,
2023
                                                            File No. 333-274230

       Dear Daniel J. O'Connor:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tim
Buchmiller at (202) 551-3635 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Raymond Bogenrief, Esq.